CartiHeal completed a US $15MM financing round. Funds will support ongoing manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C™ cartilage regeneration technology.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
The cell-free, off-the-shelf Agili-C product has been successfully implanted ~200 patients throughout the EU, to date. Agili-C is indicated to treat cartilage and osteochondral defects in degenerative and non-degenerative lesions. Results from procedures in the knee, ankle and great toe indicate regeneration of hyaline cartilage and its underlying subchondral bone, as well as improvement in pain levels and reduction of related symptoms.
Source: CartiHeal Ltd.
Past fundings for CartiHeal occurred in 1Q12 ($5MM), 3Q12 ($10MM) and 4Q13 ($5MM).
CartiHeal completed a US $15MM financing round. Funds will support ongoing manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C™ cartilage regeneration technology.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical...
CartiHeal completed a US $15MM financing round. Funds will support ongoing manufacturing scale-up, EU product commercialization in 2017 and clinical studies in new therapeutic areas for Agili-C™ cartilage regeneration technology.
The investment was led by Johnson & Johnson Innovation and existing investors Elron, Accelmed, Access Medical Ventures and Peregrine Ventures.
The cell-free, off-the-shelf Agili-C product has been successfully implanted ~200 patients throughout the EU, to date. Agili-C is indicated to treat cartilage and osteochondral defects in degenerative and non-degenerative lesions. Results from procedures in the knee, ankle and great toe indicate regeneration of hyaline cartilage and its underlying subchondral bone, as well as improvement in pain levels and reduction of related symptoms.
Source: CartiHeal Ltd.
Past fundings for CartiHeal occurred in 1Q12 ($5MM), 3Q12 ($10MM) and 4Q13 ($5MM).
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.